CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and ExhibitsItem 9.01
|99.1||Press release issued by the Company on March29, 2018.|
CATALYST PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d557996dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome CORAL GABLES,…To view the full exhibit click
About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.